Lerman C - Search Results

1

Transferability of Ancestry-Specific and Cross-Ancestry CYP2A6 Activity Genetic Risk Scores in African and European Populations.

El-Boraie A, Chenoweth MJ, Pouget JG, Benowitz NL, Fukunaga K, Mushiroda T, Kubo M, Nollen NL, Sanderson Cox L, Lerman C, Knight J, Tyndale RF. El-Boraie A, et al. Among authors: lerman c. Clin Pharmacol Ther. 2021 Oct;110(4):975-985. doi: 10.1002/cpt.2135. Epub 2021 Jan 1. Clin Pharmacol Ther. 2021. PMID: 33300144 Free PMC article.

2

Individual differences in nicotine intake per cigarette.

Patterson F, Benowitz N, Shields P, Kaufmann V, Jepson C, Wileyto P, Kucharski S, Lerman C. Patterson F, et al. Among authors: lerman c. Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):468-71. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12750245

3

Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.

Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Miksys S, et al. Among authors: lerman c. Neuropharmacology. 2003 Jul;45(1):122-32. doi: 10.1016/s0028-3908(03)00136-9. Neuropharmacology. 2003. PMID: 12814665

4

Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial.

Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, Benowitz N. Lerman C, et al. Ann Intern Med. 2004 Mar 16;140(6):426-33. doi: 10.7326/0003-4819-140-6-200403160-00009. Ann Intern Med. 2004. PMID: 15023708 Clinical Trial.

5

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Malaiyandi V, et al. Among authors: lerman c. Mol Psychiatry. 2006 Apr;11(4):400-9. doi: 10.1038/sj.mp.4001794. Mol Psychiatry. 2006. PMID: 16402128 Clinical Trial.

6

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Lerman C, et al. Clin Pharmacol Ther. 2006 Jun;79(6):600-8. doi: 10.1016/j.clpt.2006.02.006. Epub 2006 May 11. Clin Pharmacol Ther. 2006. PMID: 16765148 Clinical Trial.

7

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF. Lee AM, et al. Among authors: lerman c. Biol Psychiatry. 2007 Sep 15;62(6):635-41. doi: 10.1016/j.biopsych.2006.10.005. Epub 2007 Jan 16. Biol Psychiatry. 2007. PMID: 17223085 Clinical Trial.

8

An association of CYP2A6 genotype and smoking topography.

Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. Strasser AA, et al. Among authors: lerman c. Nicotine Tob Res. 2007 Apr;9(4):511-8. doi: 10.1080/14622200701239605. Nicotine Tob Res. 2007. PMID: 17454707

9

CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy.

Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. Lee AM, et al. Among authors: lerman c. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1312-4. doi: 10.1158/1055-9965.EPI-07-0188. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17548706 No abstract available.

10

CHRNA4 and tobacco dependence: from gene regulation to treatment outcome.

Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, Benowitz NL, Stitzel J, Bryan A, McGeary J, Haughey HM. Hutchison KE, et al. Among authors: lerman c. Arch Gen Psychiatry. 2007 Sep;64(9):1078-86. doi: 10.1001/archpsyc.64.9.1078. Arch Gen Psychiatry. 2007. PMID: 17768273

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

429 results

Search Page